Monitoring May Replace Surgery for Early Cancer

Patients with low-risk breast cancer may eventually opt for active surveillance instead of immediate surgery.

Updated on Oct. 30, 2026 in Cancer

Isometric editorial illustration featuring a clean diagnostic scanning portal in a sterile, minimalist clinical setting. — Researchers in the United States are testing if active surveillance can safely replace immediate surgery for patients diagnosed with low-risk breast cancer. AI Illustration. Upload story photo >

Live Poll

Would you trust a doctor’s recommendation to monitor early-stage cancer rather than choosing immediate surgery?

Researchers are investigating if active surveillance can replace surgery for low-risk, non-invasive breast cancers known as ductal carcinoma in situ. Patients in the study receive regular imaging and low-dose hormone therapy to monitor for disease progression instead of immediate operation.

Why it matters

Ductal carcinoma in situ represents roughly 35% of all new breast cancer cases, and this study seeks to determine if many patients are currently being overtreated. By using active surveillance, clinicians aim to avoid unnecessary surgery while still effectively preventing the development of invasive cancer.

This active surveillance clinical trial monitors patients with ductal carcinoma in situ who opt for low-dose hormone therapy and imaging rather than immediate surgery. It addresses a diagnosis that accounts for 75,000 cases annually, though final outcomes regarding long-term invasive cancer risk remain unknown.

The players

Montefiore Einstein Comprehensive Cancer Center

A research institution specializing in oncology treatments and conducting the current active surveillance trial.

The details

The approach utilizes frequent imaging, including mammograms or MRIs, every six months to watch for any signs of progression. If the cancer shows evidence of changing or growing during this monitoring, patients undergo surgery as a secondary step. This protocol intends to manage the early-stage condition while reducing the potential for overtreatment in patients whose cancers may never have become invasive.

Patients participate in imaging or mammograms every 6 months.

Health Landscape

This study shifts the treatment paradigm for ductal carcinoma in situ by challenging the standard surgical treatment protocol that has long dominated clinical practice. It reflects a broader trend in oncology toward minimizing aggressive interventions for early, low-risk conditions.

If you or a loved one are diagnosed with non-invasive breast cancer, ask your oncologist if active surveillance is an appropriate consideration for your specific profile. These decisions should always be made in close consultation with your physician, who can evaluate the risks and benefits of delaying surgery versus immediate intervention.

The takeaway

Ductal carcinoma in situ is an early form of cancer that may not require immediate surgery in all instances. Patients should discuss the risks and potential benefits of active surveillance protocols with their healthcare team to determine the best path for their individual health.